Skip to main content

Development of Collagenase Polymeric nanocapsules as Therapeutics

Project description

Treatment of scleroderma with collagenase nanocapsules

Scleroderma, or systemic sclerosis, is a chronic connective tissue autoimmune rheumatic disease. Hardening of the skin is the most visible manifestation of the disease, associated with an abnormal accumulation of collagen. Treatment involves the use of proteolytic enzymes such as collagenase, able to digest collagen fibres. However, the labile nature of collagenase compromises its activity in the human body. The goal of the EU-funded DECOMPACT project is to develop and commercialise an improved treatment for scleroderma which involves polymeric collagenase nanocapsules that release protected encapsulated enzymes after UVA irradiation. Novel nanodevices will combine the ability of the proteolytic enzyme to degrade collagen with the immunosuppressive and anti-inflammatory effects of UVA.

Call for proposal

ERC-2018-PoC
See other projects for this call

Host institution

UNIVERSIDAD COMPLUTENSE DE MADRID
Address
Avenida De Seneca 2
28040 Madrid
Spain

See on map

Activity type
Higher or Secondary Education Establishments
EU contribution
€ 149 611

Beneficiaries (1)

UNIVERSIDAD COMPLUTENSE DE MADRID
Spain
EU contribution
€ 149 611
Address
Avenida De Seneca 2
28040 Madrid

See on map

Activity type
Higher or Secondary Education Establishments